Engineered Probiotic Bacteria Show Promise in Fighting Pancreatic Cancer

Researchers at the University of Chicago have engineered a strain of Bifidobacterium longum to function as a localized drug delivery system for pancreatic cancer, according to a study published July 23 in Science Advances. By leveraging the bacteria’s natural affinity for low-oxygen environments, the team successfully concentrated an immune-stimulating cytokine directly within tumor tissue in murine models, effectively slowing tumor progression.

• Engineered Bifidobacterium longum (BifidoSumIL-2) acts as a microscopic “drug factory,” producing therapeutic molecules only within the hypoxic environment of a solid tumor.
• The treatment selectively activates cancer-fighting CD8+ T cells while limiting the activation of regulatory T cells that often suppress immune responses.
• Preclinical results indicate superior efficacy when BifidoSumIL-2 is integrated with established oncological protocols, including chemotherapy, radiotherapy, and anti-PD-L1 immunotherapy.

Biological Mechanism of Tumor-Targeted Therapy

Pancreatic cancer remains especially difficult to treat due to its characteristically “cold” tumor microenvironment, which prevents immune cells from mounting a strong attack. The study, led by researchers at the University of Chicago, addresses this barrier through a synthetic biology approach. The team engineered Bifidobacterium longum—a common probiotic—to secrete a modified form of interleukin-2 (IL-2), designated as SumIL-2.

Traditional IL-2 therapy can cause harmful side effects and may activate immune cells that suppress the antitumor response. By utilizing an obligate anaerobe, the research team ensures the therapy is concentrated within the tumor. “Bifidobacterium is an obligate anaerobe, so it doesn’t grow in the presence of oxygen,” explained Mark Mimee, PhD, Assistant Professor of Microbiology at the University of Chicago. Because healthy, oxygenated tissues inhibit the growth of these bacteria, the systemic injection leads to bacterial clearance in non-target areas, effectively limiting the drug’s activity to the hypoxic tumor core.

Synergy with Standard of Care

The clinical potential of BifidoSumIL-2 extends beyond monotherapy. According to findings published in Science Advances, the integration of this bacterial delivery platform with standard oncology regimens—specifically chemotherapy and radiation—produced a more robust therapeutic response than any single modality. Ralph Weichselbaum, MD, the Daniel K. Ludwig Distinguished Service Professor and Chair of Radiation and Cellular Oncology at the University of Chicago, noted that the combination strategy is central to the therapy’s clinical promise. The bacteria not only reshape the tumor microenvironment by increasing the activity of CD8+ T cells but also work with concurrent treatments.

Regulatory Hurdles and Future Development

While the preclinical data demonstrate significant tumor suppression in animal models, the transition to human clinical trials requires rigorous evaluation. Future research must address the long-term safety, potential for off-target effects, and the durability of the induced immune response. The development of “bugs as drugs” represents a significant shift in synthetic biology, yet it necessitates a robust framework for regulatory compliance.

The progression of this study highlights the necessity of interdisciplinary collaboration between microbiologists, immunologists, and clinicians. The ability to turn a benign probiotic into a precision tool for the delivery of potent cytokines offers a novel pathway for managing solid tumors that have historically remained refractory to conventional immunotherapy.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.